Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy
1998

Insulin-like Growth Factor in Breast Cancer Patients Undergoing Chemotherapy

Sample size: 60 publication Evidence: moderate

Author Information

Author(s): J-Ph Peyrat, F Revillion, J Bonneterre

Primary Institution: Centre Oscar Lambret

Hypothesis

Does chemotherapy affect plasma IGF-1 concentrations in breast cancer patients?

Conclusion

Chemotherapy does not significantly decrease plasma IGF-1 concentrations in breast cancer patients.

Supporting Evidence

  • IGF-1 levels decreased by 10% between the first and second courses of chemotherapy.
  • Median IGF-1 level before surgery was significantly higher than during chemotherapy.
  • Chemotherapy did not significantly alter IGF-1 levels compared to hormonal treatments.

Takeaway

The study looked at breast cancer patients and found that chemotherapy doesn't lower a certain growth factor in their blood like some other treatments do.

Methodology

Patients received six cycles of adjuvant chemotherapy, and blood samples were collected to measure IGF-1 levels.

Limitations

The study only assessed IGF-1 levels during chemotherapy and did not explore other potential influences on IGF-1 concentrations.

Participant Demographics

Median age of participants was 51 years.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication